Loading organizations...
§ Venture Capital · Changzhou Pt, China
Invests in synthetic biology startups, targeting food and pharmaceutical ingredients.
Changzhou Qihang Synthetic Biology Venture Capital Fund is an investment firm based in Changzhou, Jiangsu Province, China, that provides early-stage and growth equity funding to startups operating within the synthetic biology sector. The firm primarily targets biotechnology companies developing specialized food ingredients, such as alternative sweeteners, as well as advanced pharmaceutical and health components. To support technology development and market expansion, the fund recently led an angel financing round worth tens of millions of yuan for portfolio company YouTian Bio to scale its thaumatin production. Additionally, the firm participated in a Series C financing round of several hundred million yuan for Huaguan Bio, investing alongside recognizable institutional backers including SoftBank Ventures Asia, SDIC Innovation, and Yangtze River Capital. The venture capital fund's exact founding year and the names of its original managing founders have not been publicly disclosed.
The fund has co-invested alongside firms such as SoftBank Ventures Asia, Shunxi Fund, SDIC Venture Capital, Guotou, and Yangtze Capital in various funding rounds.
Yes, Wang Chunping is identified as a partner of Changzhou Qihang Synthetic Biology Venture Capital Fund.
The fund has co-invested alongside firms such as SoftBank Ventures Asia, Shunxi Fund, SDIC Venture Capital, Guotou, and Yangtze Capital in various funding rounds.
Yes, Wang Chunping is identified as a partner of Changzhou Qihang Synthetic Biology Venture Capital Fund.
The fund has been noted for its participation in significant financing rounds. For instance, it was a joint investor in a funding round for a dark spot-correcting ingredient supplier backed by Proya, as well as in an angel round funding for YouTian Bio. Additionally, it contributed to the Series B funding round for Huaguan Biology.
Changzhou Qihang Synthetic Biology Venture Capital Fund frequently co-invests with other prominent investment firms. Its partners in various funding initiatives have included SoftBank Ventures Asia, Shunxi Fund, SDIC Venture Capital, Guotou, and Yangtze Capital, demonstrating a collaborative approach to venture financing.
Wang Chunping is identified as a partner of the Changzhou Qihang Synthetic Biology Venture Capital Fund, indicating key leadership within the organization. This partnership structure facilitates the fund's investment strategies and portfolio management.
Through its strategic investments, the fund aims to accelerate innovation and commercialization within the synthetic biology ecosystem. Its consistent activity in funding rounds underscores its commitment to nurturing promising ventures in this specialized technological area.
Changzhou Qihang Synthetic Biology Venture Capital Fund has 1 tracked investment across 1 company. The latest tracked deal is $14.4M Series C in Huaguan Biotechnology in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 4, 2026 | Huaguan Biotechnology | $14.4M Series C | — | Changjiang Capital, SDIC Venture Capital, Shunxi Fund, Zhuhai Hengqin Softbank Xinchuang Equity Investment Management Enterprise |